Mayer, Josephine, Mbizvo, Gashirai K 
ORCID: 0000-0002-9588-2944, Bucci, Tommaso ORCID: 0000-0003-2895-6234, Marson, Anthony and Lip, Gregory YH
(2024)
Association of antiseizure medications and adverse cardiovascular events: A global health federated network analysis.
Epilepsia.
|
PDF
Epilepsia - 2024 - Mayer - Association of antiseizure medications and adverse cardiovascular events A global health.pdf - Open Access published version Download (1MB) | Preview |
Abstract
<jats:title>Abstract</jats:title><jats:sec><jats:title>Objective</jats:title><jats:p>A diagnosis of epilepsy has been associated with adverse cardiovascular events (CEs), but the extent to which antiseizure medications (ASMs) may contribute to this is not well understood. The aim of this study was to compare the risk of adverse CEs associated with ASM in patients with epilepsy (PWE).</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>A retrospective case–control cohort study was conducted using TriNetX, a global health federated network of anonymized patient records. Patients older than 18 years, with a diagnosis of epilepsy (International Classification of Diseases, 10th Revision code G40) and a medication code of carbamazepine, lamotrigine, or valproate were compared. Patients with cardiovascular disease prior to the diagnosis of epilepsy were excluded. Cohorts were 1:1 propensity score matched (PSM) according to age, sex, ethnicity, hypertension, heart failure, atherosclerotic heart disease, atrial and cardiac arrythmias, diabetes, disorders of lipoprotein metabolism, obesity, schizophrenia and bipolar disorder, medications, and epilepsy classification. The primary outcome was a composite of adverse CEs (ischemic stroke, acute ischemic heart disease, and heart failure) at 10 years. Cox regression analyses were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) following 1:1 PSM.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Of 374 950 PWE included; three cohorts were established after PSM: (1) carbamazepine compared to lamotrigine, <jats:italic>n</jats:italic> = 4722, mean age 37.4 years; (2) valproate compared to lamotrigine, <jats:italic>n</jats:italic> = 5478, mean age 33.9 years; and (3) valproate compared to carbamazepine, <jats:italic>n</jats:italic> = 4544, mean age 37.0 years. Carbamazepine and valproate use were associated with significantly higher risk of composite cardiovascular outcome compared to lamotrigine (HR = 1.390, 95% CI = 1.160–1.665 and HR = 1.264, 95% CI = 1.050–1.521, respectively). Valproate was associated with a 10‐year higher risk of all‐cause death than carbamazepine (HR = 1.226, 95% CI = 1.017–1.478), but risk of other events was not significantly different.</jats:p></jats:sec><jats:sec><jats:title>Significance</jats:title><jats:p>Carbamazepine and valproate were associated with increased CE risks compared to lamotrigine. Cardiovascular risk factor monitoring and careful follow‐up should be considered for these patients.</jats:p></jats:sec>
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | carbamazepine, epilepsy, lamotrigine, stroke, valproate |
| Divisions: | Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 28 Feb 2024 10:01 |
| Last Modified: | 29 Feb 2024 11:25 |
| DOI: | 10.1111/epi.17922 |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3178921 |
Dimensions
Dimensions
